RxDoctor Payments Data

Edward Chu, MD

Interventional Cardiology · Newport News, VANPI 1487640272

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,291 of the $4,622 with a category attached, or 71.2%. 25 manufacturers reported payments, led by Abbott at 26.8% of the total. Reporting peaked in 2023 at $1,198 and has fallen 60.5% since, to $473 in 2025. That places this record below the midpoint for interventional cardiology clinicians in VA, where the typical reported total is $4,743.

$4,622in general payments, 2019–2025

Across 96 payments — averaging $48.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Abiomed$577
  • Biotronik Inc.$518
  • Atricure, Inc.$427
  • Johnson & Johnson$236
  • Boston Scientific$210
  • plus $1K from 19 others
$310,512in research payments, 2019–2025

Across 35 payments — averaging $8871.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • American Regent$164K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$81K
  • Boehringer Ingelheim International GmbH$65K

What the payments were for

  • Travel & lodging$1,30728%
  • Food & beverage$3,29171%
  • Education$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,622 in reported general payments places this provider in the 45th percentile of 176 interventional cardiology providers in Virginia.

See all interventional cardiology providers in Virginia

Medicare billing

Part B allowed, 2024
$239,116
Medicare patients
3,296
Services billed
6,255

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban205$260,921
EliquisApixaban216$246,509
EntrestoSacubitril/Valsartan65$80,162
MultaqDronedarone Hcl36$56,196
FarxigaDapagliflozin Propanediol17$15,841
Metoprolol Succinate549$6,616
Ranolazine ErRanolazine38$4,892
Diltiazem 24hr Er (Cd)Diltiazem Hcl162$3,761
Prasugrel Hcl12$2,665
Isosorbide Mononitrate ErIsosorbide Mononitrate190$2,537
Valsartan70$1,638
Amlodipine Besylate198$1,238
ClopidogrelClopidogrel Bisulfate134$1,091
Atorvastatin Calcium155$1,091
Carvedilol142$1,060

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$236$260,921205 claims
PfizerEliquis$182$246,509216 claims
NovartisEntresto$55$80,16265 claims
Sanofi-aventis U.S. LLCMultaq$13$56,19636 claims
AstraZenecaFarxiga$207$15,84117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 176 interventional cardiology providers in Virginia.

Other interventional cardiology in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →